Evidence map›Paper›PMID 27990091›Full record

ReviewJournal of the Turkish German Gynecological Association2016

Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer.

Darren Micallef, Sarah Micallef, Pierre Schembri-Wismayer, Jean Calleja-Agius

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of the Turkish German Gynecological Association, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical trial.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2021
    Trial
  2. Review
  3. Article
  4. Review
  5. Metformin and Breast Cancer: Molecular Targets.Journal of mammary gland biology and neoplasia · 2019
    Review
  6. Risk Reduction Strategies in Breast Cancer Prevention.European journal of breast health · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Darren MicallefDepartment of Anatomy, Faculty of Medicine and Surgery, University of Malta, Tal-Qroqq, Msida, Malta.
Sarah MicallefDepartment of Anatomy, Faculty of Medicine and Surgery, University of Malta, Tal-Qroqq, Msida, Malta.
Pierre Schembri-WismayerDepartment of Anatomy, Faculty of Medicine and Surgery, University of Malta, Tal-Qroqq, Msida, Malta.
Jean Calleja-AgiusDepartment of Anatomy, Faculty of Medicine and Surgery, University of Malta, Tal-Qroqq, Msida, Malta.
University of Malta · MT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent evidence shows that commonly prescribed drugs, such as non-steroidal anti-inflammatory drugs (NSAIDs), metformin, and statins, may have beneficial roles in the primary chemoprevention of breast cancer. Therefore, these drugs could potentially be used in addition to the hormonal drugs currently used for this purpose (namely, selective estrogen receptor modulators and aromatase inhibitors) due to their alternative mechanisms of action.

Indexed as

anti-inflammatory agentsbreast neoplasmsChemoprophylaxishydroxymethylglutaryl-CoA reductase inhibitorsmetforminnon-steroidal

Identifiers

PMID27990091
PMCPMC5147761
OpenAlexW2560184281

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.